Literature DB >> 16187175

Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B.

Rosa Zampino, Emanuele Durante Mangoni, Aldo Marrone, Riccardo Utili, Giuseppe Ruggiero, Luigi Elio Adinolfi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16187175     DOI： 10.1007/s10620-005-2939-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

Review 1.  Kinetics of the immune response during HBV and HCV infection.

Authors:  Antonio Bertoletti; Carlo Ferrari
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

2.  Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B.

Authors:  A Erhardt; U Reineke; D Blondin; W H Gerlich; O Adams; T Heintges; C Niederau; D Häussinger
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B.

Authors:  S Rossol; G Marinos; P Carucci; M V Singer; R Williams; N V Naoumov
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

4.  Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?

Authors:  D R Milich; J E Jones; J L Hughes; J Price; A K Raney; A McLachlan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment.

Authors:  Rosa Zampino; A Marrone; G Cirillo; E Miraglia del Giudice; R Utili; P Karayiannis; T J Liang; G Ruggiero
Journal:  J Viral Hepat       Date:  2002-05       Impact factor: 3.728

6.  Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.

Authors:  M A Rico; J A Quiroga; D Subirá; S Castañón; J M Esteban; M Pardo; V Carreño
Journal:  Hepatology       Date:  2001-01       Impact factor: 17.425

7.  Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.

Authors:  C Boni; A Penna; G S Ogg; A Bertoletti; M Pilli; C Cavallo; A Cavalli; S Urbani; R Boehme; R Panebianco; F Fiaccadori; C Ferrari
Journal:  Hepatology       Date:  2001-04       Impact factor: 17.425

8.  Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection.

Authors:  A Marrone; R Zampino; G Luongo; R Utili; P Karayiannis; G Ruggiero
Journal:  Intervirology       Date:  2003       Impact factor: 1.763

9.  Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B.

Authors:  A Penna; G Del Prete; A Cavalli; A Bertoletti; M M D'Elios; R Sorrentino; M D'Amato; C Boni; M Pilli; F Fiaccadori; C Ferrari
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

10.  Cytokine gene polymorphisms in patients infected with hepatitis B virus.

Authors:  Ziv Ben-Ari; Eytan Mor; Orit Papo; Batia Kfir; Jaqueline Sulkes; Anat R Tambur; Ran Tur-Kaspa; Tirza Klein
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.